Linda Marbán, Ph.D., is a distinguished scientist and business leader who currently serves as the Chief Executive Officer of Capricor Therapeutics, Inc. Dr. Marbán has been at the helm of Capricor since 2007, guiding the company through its mission to develop transformative cell and exosome-based therapeutics for the treatment of rare diseases. With a strong academic background, she earned her Ph.D. in Biochemistry from the University of California, Los Angeles (UCLA), where she also completed a postdoctoral fellowship in Molecular Cardiology. Her deep understanding of cardiovascular biology and regenerative medicine has been instrumental in steering Capricor's research and development efforts. Under Dr. Marbán's leadership, Capricor has made significant strides in advancing its clinical programs, particularly in the field of Duchenne muscular dystrophy (DMD). One of her notable achievements includes the development of CAP-1002, an allogeneic cardiosphere-derived cell therapy that has shown promising results in clinical trials for DMD. Her strategic vision has also led to the expansion of Capricor's portfolio into exosome-based technologies, aiming to harness the potential of these naturally occurring vesicles for therapeutic applications. Dr. Marbán's role extends beyond the scientific realm; she has been pivotal in securing funding and forging partnerships that have propelled Capricor's growth and innovation. Her dedication to translating cutting-edge research into viable treatments underscores her commitment to improving patient outcomes and advancing the field of regenerative medicine.